Bench to Market Webinar Series: Antibody–Bottlebrush Conjugates for Targeted Cancer Therapy

Title: Antibody–Bottlebrush Conjugates for Targeted Cancer Therapy

Abstract: Antibody–drug conjugates (ADCs) are powerful targeted therapies but are limited by narrow payload diversity and chemical constraints. In this talk, I will introduce antibody–bottlebrush prodrug conjugates (ABCs) that overcome these barriers. ABCs feature antibodies covalently linked to polymeric bottlebrush prodrugs carrying diverse, tunable payloads at ultra-high drug-to-antibody ratios without compromising antibody function. This design enables precise tumor targeting, superior efficacy, and minimal toxicity in preclinical models, offering a promising next-generation therapeutic strategy.

Bio: Bin Liu is an Assistant Professor in the Center for Nuclear Receptors and Cell Signaling and the Department of Biology and Biochemistry at the University of Houston. He also holds joint appointments with the Departments of Chemistry and Biomedical Engineering and is an active faculty member in the Materials Science and Engineering program and the Center of Excellence in Polymer Chemistry. He earned his Ph.D. in Chemistry from the University of Massachusetts Amherst and completed postdoctoral research at MIT. Dr. Liu’s research integrates chemistry, bioconjugation, protein engineering, and cancer immunotherapy to advance precision therapeutics. His work centers on the rational molecular design of next-generation antibody-based conjugates across multiple length scales, including small molecules, polymers, and nanoparticles, to enable targeted and effective cancer therapy. Register here: https://us06web.zoom.us/webinar/register/WN_UQuxI6vIRsSj_3jozOeEhA#/registration